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We report a case of a child survival after extracorporeal membrane oxygenation (ECMO) support of 25 days for cardiopulmonary
failure and septic shock in the context of juvenile myelomonocytic leukemia (JMML). ECMO support is still a matter of debate for
the management of septic patients with malignancy. However, these patients are at increased risk for early death secondary to
pulmonary complications due to leukostasis, direct pulmonary inﬁltration with WBC, and systemic inﬂammatory response
syndrome following malignant cell lysis. Despite the high risk of complications, ECMO support must be discussed as part of
management, providing better outcome in this group of patients.
1. Introduction
Extracorporeal membrane oxygenation (ECMO) support is
still a matter of debate for the management of septic patients
with malignancy. However, these patients are at increased
risk for early death secondary to pulmonary complications
due to leukostasis, direct pulmonary inﬁltration with WBC,
and systemic inﬂammatory response syndrome following
malignant cell lysis [1].
We report a case of successful management of a child
with juvenile myelomonocytic leukemia (JMML), who re-
quired prolonged ECMO support secondary to cardiopul-
monary failure following initiation of chemotherapy.
2. Patients’ Medical Report
A 4-year-old boy presented with an intermittent fever for
two weeks, cold symptoms, and loss of appetite. On
physical examination, the child was found moderately
dehydrated, tachycardic, and tachypneic and demon-
strated a hepatosplenomegaly. His peripheral blood tests
showed 10% myeloid blasts with WBC (16.2 ×109/L),
severe anemia (Hb 2.8 g/dL), and thrombocytopenia
(platelets 6 ×109/L), as well as a monocyte count of
4.61 × 109/l. A bone marrow aspiration was performed
and revealed 10% of myeloid blast cells. *e patient was
started on an induction regimen with cytarabine and
rasburicase. Less than 24 hours after initiation of therapy,
he developed fever and progressive respiratory failure. A
chest X-ray showed a bilateral pulmonary inﬁltration. In
the context of suspected sepsis, the broad-spectrum
antibiotic treatment was started. Echocardiography
showed signs of severe pulmonary hypertension (PHT).
Despite inotropic support, mechanical ventilation, and
early antibiotics, the patient deteriorated and was re-
ferred to our tertiary pediatric intensive care unit.
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At arrival, his general condition was critical with signs
of multiorgan failure and severe lactic acidosis. *e neu-
rological status appeared to be normal. His acute respi-
ratory distress syndrome necessitated high-pressure
ventilation (Figure 1(a)). Despite optimized conventional
therapy, he rapidly developed cardiogenic shock. A veno-
arterial (VA) ECMO was initiated via neck vessel can-
nulation, and immediate improvement in oxygenation was
achieved (Figure 1(b)). ECMO ﬂow was stable between 1.2
– 1.7 L/min during the whole support period. ACTwas kept
at 180 seconds. No major bleeding complications occurred.
Mechanical ventilation was continued, and PHT therapy
was initiated with sodium nitroprusside and nitrous oxide.
First improvements in ventilation were observed on day 12
on ECMO support. On day 18, VA ECMO could be
converted to a veno-venous (VV) ECMO by using a dual
lumen Avalon ELITE cannula (MAQUET Cardiopulmo-
nary AG, Germany) (Figure 1(c)). After seven days of VV
ECMO support, the patient was successfully weaned on day
25 (Figure 1(d)). *e neurologic assessment of the patient
was limited during ECMO support due to pharmacological
sedation. Following further hemodynamic improvement
and weaning of sedation, the patient demonstrated a
quadriplegia, global aphasia, and conjugate eye deviation.
Subsequent MRI diagnostic revealed a central pontine
myelinolysis. Certainly, it was caused by dyselectrolaemia
with severe hypernatremia. Despite severe neurological
impairment, his respiratory condition improved further,
and 2 days later (day 30), he was extubated (Figure 2).
Following extubation, a bilateral vocal cord paralysis of
probably central origin was noticed.
Given the fast improvement of the patient, the initially
paused chemotherapy with cytarabine was restarted early, thus
allowing a cytogenetic remission on day 21 of ECMO support.
On day 34 of hospitalization, the patient was referred for
evaluation for allogeneic hematopoietic stem cell trans-
plantation to the transplantation center. A genetic testing
revealed a KRAS and SETBP1 mutation. Given the severe
neurological impairment, the decision was taken to proceed
with bridging chemotherapy until improvement of the
neurological status could be observed.
Five weeks later, the patient’s clinical condition was normal
with a remarkably improved neurological status andnormalized
vocal chord function. *e patient could walk, even drive a 3-
wheel bike, while his cognitive functionwas still impaired with a
stammer requiring further speech and language therapy.
Six months later, he underwent allogeneic hematopoietic
stem cell transplantation with a 10/10 HLA-matched
Figure 1: (a) Chest X-ray on admission. (b) Chest X-ray after ECMO cannulation via neck vessels. (c) Chest X-ray after conversion to veno-
venous ECMO by using single venous neck cannula. (d) Chest X-ray after ECMO weaning.
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unrelated donor donating bone marrow. *e conditioning
comprised ﬂudarabine, targeted busulfan, and melphalan
including rabbit ATG. He engrafted at day +26 and +23 with
neutrophils and platelets of donor origin. *e child was
discharged home with minor cognitive impairment.
3. Discussion
To our knowledge, this is the ﬁrst report of survival after
prolonged ECMO support (25 days) in a child with JMML and
cardio-respiratory failure secondary to tumor lysis syndrome.
Meister et al. published a case report of an infant with JMML,
who was on ECMO support for 5 days and died because of
pulmonary failure [2]. JMML is a rare, aggressive, clonal
hematopoietic disorder of childhood characterized by over-
production of monocytic and granulocytic cells with organ
inﬁltration, such as spleen, liver, and lungs [3]. A life-
threatening complication is the occurrence of a TLS arising
most commonly after initiation of chemotherapy. Mortality is
reported between 21–66% [4]. Generally, the main principles
of management include early recognition of metabolic and
renal complications and the prompt administration of ino-
tropic and respiratory support. However, there are no data and
recommendations on the application of ECMO therapy in
those cases. Considering that in JMML hemorrhagic and
thrombotic complications are frequent and survival for re-
fractory shock in pediatric patients with or without sepsis is
limited, the initiation of ECMO therapy is debatable andmight
be withheld from those patients. *e reported case demon-
strates that successful management of cardiorespiratory failure
in the setting of TLS in JMML can be achieved. Early ad-
ministration of ECMO should be considered and allows for
immediate stabilization of cardiorespiratory function in this
context. Despite the high risk of hemorrhagic and throm-
boembolic complications in patients with JMML, prolonged
ECMO support should be attempted.
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Figure 2: Chest X-ray after extubation.
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